# IRIDEX (IRIX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IRIX
## Company Profile
- Ticker: IRIX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: MedTech, Ophthalmology
## Stock Data
- Close: 0.7 USD
- Market cap: 20365626.06 USD
- Last updated: 2026-09-04
## Business Overview
### Ophthalmic Laser Technology Company
Iridex develops, manufactures, and markets laser-based medical systems, delivery devices, and accessories for ophthalmology. Its products are used by eye-care specialists to treat glaucoma, diabetic macular edema, and other retinal diseases.
### MicroPulse Technology
The company's proprietary MicroPulse technology divides laser energy into controlled pulses separated by rest periods. This approach is designed to deliver a therapeutic effect while limiting excess heat accumulation and collateral tissue damage in sensitive ocular structures.
### Glaucoma Portfolio
Iridex's glaucoma franchise is built around the Cyclo G6 laser system and a recurring portfolio of single-use probes. MicroPulse P3, G-Probe, and G-Probe Illuminate devices enable physicians to apply transscleral laser therapy across different glaucoma treatment settings.
### Retina Portfolio
The retina business includes PASCAL, IQ, and OcuLight laser systems together with delivery devices and consumables. These products support treatment of retinal vascular conditions and other sight-threatening diseases in both clinic and operating-room environments.
### Global Commercial Model
Iridex sells products directly in the United States and primarily through independent distributors internationally. Its commercial network reaches more than 100 countries and combines capital-equipment placements with recurring revenue from procedure-specific probes and other consumables.
## Why The Stock Is Moving

As of Sep 4, 2026, IRIX was little changed and closed at $0.7000. No new same-company headline was identified in the current news window.

## Recent News
- 2026-08-18 20:05 EST — [Iridex Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/IRIX/iridex-reports-second-quarter-2026-financial-results-72cb083a) — Source: IRIDEX
- 2026-08-04 20:05 EST — [Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026](https://biopharmsignal.com/news/IRIX/iridex-to-report-second-quarter-2026-financial-results-on-august-18-2026-99ba9bdd) — Source: IRIDEX
- 2026-07-20 11:00 EST — [Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering](https://biopharmsignal.com/news/IRIX/iridex-adds-endoprobe-handpieces-to-eyeprogpo-product-offering-deb0efd9) — Source: IRIDEX
- 2026-06-09 20:05 EST — [Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference](https://biopharmsignal.com/news/IRIX/iridex-to-present-at-the-planet-microcap-las-vegas-2026-conference-3221318c) — Source: IRIDEX
- 2026-05-19 20:05 EST — [Iridex Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/IRIX/iridex-reports-first-quarter-2026-financial-results) — Source: IRIDEX